Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35906   clinical trials with a EudraCT protocol, of which   5892   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A prospective, multicentre, randomized, open-label, non-inferiority, controlled phase III B trial carried out in parallel groups: subcutaneous versus peripheral intravenous administration.

    Summary
    EudraCT number
    2007-006153-31
    Trial protocol
    FR  
    Global end of trial date
    09 Apr 2010

    Results information
    Results version number
    v1(current)
    This version publication date
    21 Apr 2018
    First version publication date
    21 Apr 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CSC/P01/07/Mu.F
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Baxter Healthcare Corporation
    Sponsor organisation address
    1 Baxter Parkway, Deerfield, United States, 60015
    Public contact
    Clinical Trials Disclosure Call Center, Baxter Healthcare Corporation, Global_CORP_ClinicalTrialsDisclosure@baxter.com
    Scientific contact
    Clinical Trials Disclosure Call Center, Baxter Healthcare Corporation, Global_CORP_ClinicalTrialsDisclosure@baxter.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Apr 2010
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    09 Apr 2010
    Global end of trial reached?
    Yes
    Global end of trial date
    09 Apr 2010
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to demonstrate that the SC administration of 1 liter of Clinimix N9G15E is non-inferior to the peripheral IV administration of 1 liter of Clinimix N9g15E in terms of local side effects. The secondary objective was to assess safety and efficacy in terms of patients' nutritional parameters, clinical outcomes, and hydration status.
    Protection of trial subjects
    A patient could withdraw consent at any time for any reason. Patients were discontinued from the study if any of the following occurred during the course of the study: -Patient required enteral or other parenteral administration. -Patient or patient's legal authorized representative withdrew consent. -Patient enrolled in any other investigational study. -Onset of any serious or life threatening adverse event requiring discontinuation of study treatment. -Investigator's decision. -In case of the need for a second administration route switch. -Patient required therapeutic anticoagulation after enrollment in the study.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    30 Jul 2008
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    France: 120
    Worldwide total number of subjects
    120
    EEA total number of subjects
    120
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    100
    85 years and over
    20

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    The study population (geriatric) chosen represented one population with difficult venous access and where SC hydration has been effective. The population contained patients with many different disorders. Other populations with difficult venous access may benefit from the therapy (the study was not meant to be exclusive of other populations).

    Period 1
    Period 1 title
    Overall (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    SC Treatment
    Arm description
    Subcutaneous (SC) Treatment of Clinimix N9G15E at a dose of 1 liter was infused subcutaneously over 12 hours for at least 7 and up to 10 consecutive days. Infusion sites included abdominal area, thighs, back and chest and were to be changed after administration of each 1 liter bag. Subcutaneous infusions were administered with a 21 to 25 G butterfly needle or catheter.
    Arm type
    Experimental

    Investigational medicinal product name
    Clinimix N9G15E Subcutaneous
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    The Clinimix N9G15E 1 L bag contained 27.5 g amino acids with electrolytes (Na, K, Ca, Mg, and PO4) and 75 g glucose, in separate chambers, providing a total of 410 kcal/L. The final osmolarity (after mixing) was 845 mOsm/L. All 1000 mL were planned to be infused over 12 hours, resulting in a rate of infusion of approximately 83 to 84 mL/hour, not exceeding a rate of 3 mL/kg/hour.

    Arm title
    IV Treatment
    Arm description
    Intravenous (IV) Treatment of Clinimix N9G15E at a dose of 1 liter was infused via peripheral IV over 12 hours for at least 7 and up to 10 consecutive days. Peripheral IV drips were to be changed by the local implementation of the local Comite' de Liaison en Alimentation et Nutrition (CLAN) recommendations. The peripheral IV lines used for administration of Clinimix were to be used only for administration of the study test product. After administration of the final dose of test product, the peripheral IV line was to be removed and the injection site was not to be used for 48 hours.
    Arm type
    Active comparator

    Investigational medicinal product name
    Clinimix N9G15E Intravenous
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous drip use
    Dosage and administration details
    The Clinimix N9G15E 1 L bag contained 27.5 g amino acids with electrolytes (Na, K, Ca, Mg, and PO4) and 75 g glucose, in separate chambers, providing a total of 410 kcal/L. The final osmolarity (after mixing) was 845 mOsm/L. All 1000 mL were planned to be infused over 12 hours, resulting in a rate of infusion of approximately 83 to 84 mL/hour, not exceeding a rate of 3 mL/kg/hour.

    Number of subjects in period 1
    SC Treatment IV Treatment
    Started
    59
    61
    Completed
    49
    53
    Not completed
    10
    8
         Protocol Noncompliance
    -
    1
         Deaths
    1
    1
         Clinical adverse event
    3
    3
         Unknown
    2
    1
         Consent withdrawn by subject
    3
    1
         Biological adverse event
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    SC Treatment
    Reporting group description
    Subcutaneous (SC) Treatment of Clinimix N9G15E at a dose of 1 liter was infused subcutaneously over 12 hours for at least 7 and up to 10 consecutive days. Infusion sites included abdominal area, thighs, back and chest and were to be changed after administration of each 1 liter bag. Subcutaneous infusions were administered with a 21 to 25 G butterfly needle or catheter.

    Reporting group title
    IV Treatment
    Reporting group description
    Intravenous (IV) Treatment of Clinimix N9G15E at a dose of 1 liter was infused via peripheral IV over 12 hours for at least 7 and up to 10 consecutive days. Peripheral IV drips were to be changed by the local implementation of the local Comite' de Liaison en Alimentation et Nutrition (CLAN) recommendations. The peripheral IV lines used for administration of Clinimix were to be used only for administration of the study test product. After administration of the final dose of test product, the peripheral IV line was to be removed and the injection site was not to be used for 48 hours.

    Reporting group values
    SC Treatment IV Treatment Total
    Number of subjects
    59 61 120
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    84.4 ± 6.14 84.9 ± 5.92 -
    Gender categorical
    Units: Subjects
        Female
    34 44 78
        Male
    25 17 42

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    SC Treatment
    Reporting group description
    Subcutaneous (SC) Treatment of Clinimix N9G15E at a dose of 1 liter was infused subcutaneously over 12 hours for at least 7 and up to 10 consecutive days. Infusion sites included abdominal area, thighs, back and chest and were to be changed after administration of each 1 liter bag. Subcutaneous infusions were administered with a 21 to 25 G butterfly needle or catheter.

    Reporting group title
    IV Treatment
    Reporting group description
    Intravenous (IV) Treatment of Clinimix N9G15E at a dose of 1 liter was infused via peripheral IV over 12 hours for at least 7 and up to 10 consecutive days. Peripheral IV drips were to be changed by the local implementation of the local Comite' de Liaison en Alimentation et Nutrition (CLAN) recommendations. The peripheral IV lines used for administration of Clinimix were to be used only for administration of the study test product. After administration of the final dose of test product, the peripheral IV line was to be removed and the injection site was not to be used for 48 hours.

    Primary: Number of Patients with at Least One Major Local Side Effect

    Close Top of page
    End point title
    Number of Patients with at Least One Major Local Side Effect
    End point description
    Major local side effects were evaluated before the start of and at the end of an infusion. An event reported at the start of an infusion was allocated to the route of the previous administration as the "12 hour later" assessment. If an AE occurred before a change/switch of administration route, it was attributed to the previous route. The event was considered a major local side effect if, during the infusion that the major local side effect was attributed to, the subject was infused with a least 800mL of study product and the infusion was between 8 and 16 hours in duration. This endpoint was defined as the occurrence of at least 1 of the following: large edema (diameter>10cm); blistering (diameter>2cm); erythema (diameter>10cm); phlebitis; cellulitis; or strong (unbearable) pain.
    End point type
    Primary
    End point timeframe
    Day 1 to Day 11
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Patients
        number (not applicable)
    16
    27
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.059
    Method
    Fisher exact
    Confidence interval
         level
    97.5%
         sides
    1-sided
         lower limit
    -
         upper limit
    0.4

    Primary: Number of Patients by Major Local Side Effect Type

    Close Top of page
    End point title
    Number of Patients by Major Local Side Effect Type
    End point description
    Large edema (diameter > 10 cm) Blistering (diameter > 2 cm) Erythema (diameter > 10 cm)
    End point type
    Primary
    End point timeframe
    Day 1 to Day 11
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Patients
    number (not applicable)
        Large edema
    13
    5
        Blistering
    0
    0
        Erythema
    5
    2
        Unbearable pain
    0
    1
        Phlebitis
    1
    0
        Cellulitis
    1
    1
    Statistical analysis title
    Large edema
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.042
    Method
    Fisher exact
    Confidence interval
    Statistical analysis title
    Erythema
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.268
    Method
    Fisher exact
    Confidence interval
    Statistical analysis title
    Unbearable pain
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 1
    Method
    Fisher exact
    Confidence interval
    Statistical analysis title
    Phlebitis
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.492
    Method
    Fisher exact
    Confidence interval
    Statistical analysis title
    Cellulitis
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 1
    Method
    Fisher exact
    Confidence interval

    Secondary: Change from Baseline in Body Weight at End of Treatment

    Close Top of page
    End point title
    Change from Baseline in Body Weight at End of Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Kilogram (kg)
        arithmetic mean (standard deviation)
    0.8 ± 2.26
    0.4 ± 1.60
    Statistical analysis title
    Stats 1
    Statistical analysis description
    Difference from Baseline to End of Treatment
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.453
    Method
    F-test
    Confidence interval

    Secondary: Change from Baseline in Body Mass Index (BMI) at End of Treatment

    Close Top of page
    End point title
    Change from Baseline in Body Mass Index (BMI) at End of Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: kg/m2
        arithmetic mean (standard deviation)
    0.4 ± 0.94
    0.2 ± 0.62
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.465
    Method
    F-test
    Confidence interval

    Secondary: Change from Baseline in Transthyretin at End of Treatment

    Close Top of page
    End point title
    Change from Baseline in Transthyretin at End of Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: g/L
        arithmetic mean (standard deviation)
    0.02 ± 0.038
    0.01 ± 0.048
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.26
    Method
    F-test
    Confidence interval

    Secondary: Change from Baseline in Albumin at End of Treatment

    Close Top of page
    End point title
    Change from Baseline in Albumin at End of Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: g/L
        arithmetic mean (standard deviation)
    0 ± 3.6
    -0 ± 3.3
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.854
    Method
    F-test
    Confidence interval

    Secondary: Change from Baseline in Transferrin at End of Treatment

    Close Top of page
    End point title
    Change from Baseline in Transferrin at End of Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: umol/L
        arithmetic mean (standard deviation)
    2.1 ± 3.1
    0.4 ± 4.5
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.17
    Method
    F-test
    Confidence interval

    Secondary: Change from Baseline in Lymphocytes at End of Treatment

    Close Top of page
    End point title
    Change from Baseline in Lymphocytes at End of Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: cells/mm3
        arithmetic mean (standard deviation)
    -11 ± 533.1
    -69 ± 368.7
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.567
    Method
    f-test
    Confidence interval

    Secondary: Change from Baseline in Clinical Laboratory Hydration Parameters

    Close Top of page
    End point title
    Change from Baseline in Clinical Laboratory Hydration Parameters
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: mmol/L
    arithmetic mean (standard deviation)
        Potassium
    0.24 ± 0.494
    0.23 ± 0.397
        Chloride
    0.0 ± 3.3
    0 ± 9.9
        Bicarbonate
    -0.4 ± 3.28
    0.7 ± 4.67
        Calcium
    0.04 ± 0.188
    0 ± 0.096
        Magnesium
    0.05 ± 0.089
    0.05 ± 0.082
        Phosphorus
    0.13 ± 0.245
    0.09 ± 0.184
        Glucose
    0.12 ± 2.244
    0.61 ± 2.112
    Statistical analysis title
    Potassium
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.63
    Method
    F-test
    Confidence interval
    Statistical analysis title
    Chloride
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.576
    Method
    F-test
    Confidence interval
    Statistical analysis title
    Bicarbonate
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.27
    Method
    F-test
    Confidence interval
    Statistical analysis title
    Calcium
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.611
    Method
    F-test
    Confidence interval
    Statistical analysis title
    Magnesium
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.935
    Method
    F-test
    Confidence interval
    Statistical analysis title
    Phosphorus
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.508
    Method
    F-test
    Confidence interval
    Statistical analysis title
    Glucose
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    = 0.386
    Method
    F-test
    Confidence interval

    Secondary: Adherence (by Days) to Assigned Administration Route

    Close Top of page
    End point title
    Adherence (by Days) to Assigned Administration Route
    End point description
    Adherence to assigned administration route is defined as the number of days before any change/switch of administration route for patients who did experience a change/switch, or the total duration of treatment in days for patients who did not experience a change/switch.
    End point type
    Secondary
    End point timeframe
    Day 1 to Day 11
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Days
        arithmetic mean (standard deviation)
    7.4 ± 2.4
    5.6 ± 3
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    P-value
    < 0.001
    Method
    F-test
    Confidence interval

    Secondary: Length of Stay until Date of Discharge

    Close Top of page
    End point title
    Length of Stay until Date of Discharge
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Days
        arithmetic mean (standard deviation)
    21.3 ± 13.2
    20.8 ± 13.6
    No statistical analyses for this end point

    Secondary: Length of Stay until Date Ready for Discharge

    Close Top of page
    End point title
    Length of Stay until Date Ready for Discharge
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline and End of Treatment (Day 11)
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Days
        arithmetic mean (standard deviation)
    20.2 ± 13.3
    22.3 ± 16.2
    No statistical analyses for this end point

    Secondary: Percentage of Patients by Destination at Discharge

    Close Top of page
    End point title
    Percentage of Patients by Destination at Discharge
    End point description
    End point type
    Secondary
    End point timeframe
    Day 21/End of Study
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Destination (location)
    number (not applicable)
        Home
    32.2
    24.6
        Nursing Home
    15.3
    14.8
        Chronic Care Facility
    15.3
    11.5
        Other
    28.8
    39.3
        Remain in Ward
    0
    0
        Unknown
    8.5
    9.8
    No statistical analyses for this end point

    Secondary: Patient Survival at End of Study

    Close Top of page
    End point title
    Patient Survival at End of Study
    End point description
    End point type
    Secondary
    End point timeframe
    Day 21/End of Study
    End point values
    SC Treatment IV Treatment
    Number of subjects analysed
    59
    61
    Units: Patients
    number (not applicable)
        Deaths
    3
    5
        Censored
    56
    56
    Statistical analysis title
    Stats 1
    Comparison groups
    SC Treatment v IV Treatment
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    Method
    Parameter type
    Hazard ratio (HR)
    Point estimate
    2.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.4
         upper limit
    11.9

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Treatment Emergent
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    11
    Reporting groups
    Reporting group title
    SC Before or During Switch or Route
    Reporting group description
    -

    Reporting group title
    IV Before or During Switch or Route
    Reporting group description
    -

    Reporting group title
    SC after switch of route
    Reporting group description
    -

    Serious adverse events
    SC Before or During Switch or Route IV Before or During Switch or Route SC after switch of route
    Total subjects affected by serious adverse events
         subjects affected / exposed
    7 / 61 (11.48%)
    6 / 59 (10.17%)
    3 / 21 (14.29%)
         number of deaths (all causes)
    3
    4
    1
         number of deaths resulting from adverse events
    3
    4
    1
    Vascular disorders
    ARTERIAL DISORDER
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    THROMBOPHLEBITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    FEMORAL NECK FRACTURE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    COLORECTAL CANCER
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    OESOPHAGEAL CARCINOMA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Cardiac disorders
    ATRIAL FIBRILLATION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    CARDIAC FAILURE ACUTE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    PULMONARY EMBOLISM
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    GENERAL PHYSICAL HEALTH DETERIORATION
         subjects affected / exposed
    1 / 61 (1.64%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    Renal and urinary disorders
    RENAL FAILURE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    RENAL FAILURE ACUTE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    DIABETES MELLITUS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    HYPERKALAEMIA
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    PNEUMONIA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    SEPTIC SHOCK
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0.1%
    Non-serious adverse events
    SC Before or During Switch or Route IV Before or During Switch or Route SC after switch of route
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    42 / 61 (68.85%)
    37 / 59 (62.71%)
    11 / 21 (52.38%)
    Vascular disorders
    ARTERIAL DISORDER
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    0
    1
    DEEP VEIN THROMBOSIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    ORTHOSTATIC HYPOTENSION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    POOR VENOUS ACCESS
         subjects affected / exposed
    0 / 61 (0.00%)
    4 / 59 (6.78%)
    0 / 21 (0.00%)
         occurrences all number
    0
    4
    0
    THROMBOPHLEBITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    COLORECTAL CANCER
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    OESOPHAGEAL CARCINOMA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    General disorders and administration site conditions
    GENERAL PHYSICAL HEALTH DETERIORATION
         subjects affected / exposed
    1 / 61 (1.64%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    1
    2
    0
    HYPERTHERMIA
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    INFLAMMATION
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    INFUSION SITE CELLULITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    INFUSION SITE ERYTHEMA
         subjects affected / exposed
    5 / 61 (8.20%)
    3 / 59 (5.08%)
    0 / 21 (0.00%)
         occurrences all number
    8
    3
    0
    INFUSION SITE EXTRAVASATION
         subjects affected / exposed
    0 / 61 (0.00%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    0
    2
    0
    INFUSION SITE HAEMATOMA
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    INFUSION SITE INFLAMMATION
         subjects affected / exposed
    0 / 61 (0.00%)
    8 / 59 (13.56%)
    0 / 21 (0.00%)
         occurrences all number
    0
    9
    0
    INFUSION SITE OEDEMA
         subjects affected / exposed
    19 / 61 (31.15%)
    7 / 59 (11.86%)
    5 / 21 (23.81%)
         occurrences all number
    42
    7
    11
    INFUSION SITE PAIN
         subjects affected / exposed
    1 / 61 (1.64%)
    3 / 59 (5.08%)
    2 / 21 (9.52%)
         occurrences all number
    1
    5
    2
    INFUSION SITE REACTION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    2
    0
    INFUSION SITE VESICLES
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    1
    0
    1
    PYREXIA
         subjects affected / exposed
    2 / 61 (3.28%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    2
    2
    0
    Psychiatric disorders
    DEPRESSION
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    INSOMNIA
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Injury, poisoning and procedural complications
    DUST INHALATION PNEUMOPATHY
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    0
    FEMORAL NECK FRACTURE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Investigations
    BLOOD ALKALINE PHOSPHATASE INCREASED
         subjects affected / exposed
    0 / 61 (0.00%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    0
    2
    0
    BLOOD CREATININE INCREASED
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    BLOOD UREA INCREASED
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    C-REACTIVE PROTEIN INCREASED
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    1
    0
    1
    GAMMA-GLUTAMYLTRANSFERASE INCREASED
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    1
    THYROXINE FREE INCREASED
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    WEIGHT DECREASED
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Respiratory, thoracic and mediastinal disorders
    COUGH
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    DYSPNOEA EXERTIONAL
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    EPISTAXIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    LUNG DISORDER
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    PULMONARY EMBOLISM
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    0
    1
    Blood and lymphatic system disorders
    ANAEMIA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    CARDIAC DISORDERS
         subjects affected / exposed
    1 / 61 (1.64%)
    3 / 59 (5.08%)
    1 / 21 (4.76%)
         occurrences all number
    1
    3
    1
    ATRIAL FIBRILLATION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    CARDIAC FAILURE
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    1 / 21 (4.76%)
         occurrences all number
    0
    1
    1
    CARDIAC FAILURE ACUTE
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    Nervous system disorders
    DIZZINESS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    SYNCOPE
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    Eye disorders
    CONJUNCTIVITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Ear and labyrinth disorders
    VERTIGO
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    Gastrointestinal disorders
    ABDOMINAL PAIN UPPER
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    CONSTIPATION
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 59 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    2
    0
    2
    DIARRHOEA
         subjects affected / exposed
    4 / 61 (6.56%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    4
    2
    0
    NAUSEA
         subjects affected / exposed
    1 / 61 (1.64%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    1
    2
    0
    VOMITING
         subjects affected / exposed
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    0
    0
    1
    Renal and urinary disorders
    HAEMATURIA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    RENAL FAILURE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    1
    0
    1
    RENAL FAILURE ACUTE
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    URINARY RETENTION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    Skin and subcutaneous tissue disorders
    MUCOCUTANEOUS RASH
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Musculoskeletal and connective tissue disorders
    ARTHRALGIA
         subjects affected / exposed
    1 / 61 (1.64%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    MUSCLE SPASMS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    NECK PAIN
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Metabolism and nutrition disorders
    DEHYDRATION
         subjects affected / exposed
    2 / 61 (3.28%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    2
    1
    0
    DIABETES MELLITUS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    HYPERGLYCAEMIA
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    HYPERKALAEMIA
         subjects affected / exposed
    2 / 61 (3.28%)
    0 / 59 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    2
    0
    1
    HYPOKALAEMIA
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    HYPONATRAEMIA
         subjects affected / exposed
    2 / 61 (3.28%)
    2 / 59 (3.39%)
    0 / 21 (0.00%)
         occurrences all number
    2
    2
    0
    MALNUTRITION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    Infections and infestations
    BRONCHOPNEUMONIA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    ERYSIPELAS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    FUNGAL INFECTION
         subjects affected / exposed
    2 / 61 (3.28%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    2
    1
    0
    GASTROENTERITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    HELICOBACTER GASTRITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    LYMPHANGITIS
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    PNEUMONIA
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    PYELONEPHRITIS
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    SEPTIC SHOCK
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    SKIN INFECTION
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    URINARY TRACT INFECTION
         subjects affected / exposed
    2 / 61 (3.28%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    2
    1
    0
    VULVOVAGINAL MYCOTIC INFECTION
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA